Know the Factors that Driving the Growth of Biosimilars Market

1. Opportunity Analysis and Industry Forecast, 2016-2023 Rapid Advancements will boost Biosimilars Market Global Opportunity Analysis and Industry Forecast, 2014-2020

2. Biosimilars Market The commercialization of filgrastim biosimilars in the United States have brought the revolutionary changes in development of biosimilars. Pharmaceutical companies interested in investing into biosimilars market are now focusing on the agreement and acquisitions, in order to expand their presence in biosimilars market. Recently, the Pfizer has acquired Hospira, a global leader in biosimilars. This acquisition has strengthen the biosimilar portfolio of Pfizer. Also, it increases the global reach of Hospira through commercial capabilities, scientific expertise of Pfizer. The key companies profiled in the report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).

3. Biosimilars Market Overview Global biosimilars/follow-on-biologics market was valued at $2,552.0 million in 2014 and is expected to reach $26,551.3 million by 2020, supported by a CAGR of 49.1% during the forecast period 2015 to 2020. Biosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. Regulations for biosimilars play a vital role in maintaining the viability and balance between original and biosimilars products. Various regulatory authorities such as EMA and FDA actively regulate the biosimilars commercialization and development.   Access Full Summary : https://www.alliedmarketresearch.com/global-biosimilars-market The market is driven by factors such rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs, especially for the high priced patented drugs. However, the market growth is limited by the high cost of reference products increases the financial burden on patients as well as reimbursement service providers. The lack in economies of scale due to lower demand is a factor that results in these high costs.

4. Biosimilars Market The product segment in the biosimilars market comprises of Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Colony Stimulating Factors and others. The biosimilars applications market is segmented into blood disorders, oncology diseases, chronic and autoimmune diseases and growth hormone deficiency. The application of biosimilars in blood disease treatment is the highest revenue generating segment owing to the high-priced reference biologics and frequent application. However, biosimilars applications in autoimmune and chronic diseases exhibit the highest potential due to the changing off patent scenario. Biopharmaceutical industry is vastly dependent on the advanced technologies used in various procedures of development and manufacturing. These technologies are acting as a mandate for every single operation in biopharmaceutical and healthcare research industry. Some of the significant technologies are discussed in the report includes, Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA technology), Nuclear magnetic resonance (NMR) technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting and Bioassay. 

5. Biosimilars MarketSnapshot The Global biosimilars products market is segmented into Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, G-CSF, peptide and other biosimilars. Patent expiration is a key factor that largely influences the biosimilars market. Most of the blockbuster patents would expire by the end of 2014; a factor that would provide competitive advantage to local pharmaceutical manufacturers over global players.  Most of the lucrative products in biosimilars industries are monoclonal antibodies, G-CSF erythropoietin and peptide. These products are currently commanding the biosimilars market and have received approval for commercialization in many geographies. Companies manufacturing these biosimilars are achieving economies of scale in the market; thus, receiving cost advantage in a price sensitive market This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).

6. Biosimilars Market North America Europe Asia-Pacific LAMEA

7. Biosimilars Market Thank You! For More Details Visit us at https://www.alliedmarketresearch.com/request-sample/700 Follow Us On